ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1751

CD4 Aptamer-RORγt shRNA Chimera Inhibits IL-17 Synthesis By Human CD4+ T cells

Cong-Qiu Chu1, Pingfang Song2, Yuan K. Chou3, Xiaowei Zhang2, Roberto Meza-Romero2, Kentaro Yomogida3 and Gil Benedek2, 1Rheumatology, Oregon Health & Science Univ, Portland, OR, 2Oregon Health & Science University, Portland, OR, 3Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: T cells

  • Tweet
  • Email
  • Print
Session Information

Title: T cell Biology in Rheumatoid Arthritis and Other Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose

RNA interfering (RNAi)-mediated gene silencing holds great promise for manipulating T cells to study basic T cell biology and for developing potential T cell targeted therapeutics. However, efficient delivery of small interfering RNA (siRNA) specifically into primary T cells represents a major hurdle to the widely use of RNAi technology. We explored the use of single-stranded oligonucleotide aptamers as vehicle to deliver small hairpin RNA (shRNA) to target Th17 cells.

Methods

An RNA aptamer specifically binds to CD4 was previously selected and sequenced. siRNA to retinoic acid related orphan receptor (ROR)-γt was previously designed and tested. A cDNA encoding the CD4 aptamer and RORγt shRNA was constructed and the CD4 aptamer-RORγt shRNA (CD4-AshR-RORγt) chimera was generated using in vitro T7 RNA transcription. 2´-F-dCTP and 2´-F-dUTP were incorporated into CD4-AshR-RORγt for RNase resistance. CD4+ human T lymphoma cells, Karpas 299 constitutively expressing RORγt were tested for CD4-AshR-RORγt internalization. Human CD4+ T cells were polarized to Th17 cells for analysis of CD4-AshR-RORγt delivery efficiency and suppression of RORγt expression and IL-17 production.

Results

The CD4 aptamer and RORγt shRNA was transcribed to form a stable single chimeric aptamer-shRNA molecule, CD4-AshR-RORγt.  CD4-AshR-RORγt was labeled with flurochrome Cy3 via Cy3-CTP incorporation during RNA transcription. CD4-AshR-RORγt was specifically uptaken by CD4+ Karpas 299 cells and primary human CD4+ T cells as visualized by confocal microscopy and flow cytometry. The RORγt shRNA moiety of CD4-AshR-RORγt chimera was cleaved and released by endoribonuclease Dicer.  CD4-AshR-RORγt suppressed RORγt gene expression in Karpas 299 cells and CD4+ T cells in a dose dependent manner, but did not affect Tbox21 gene expression. Furthermore, 50-70% IL-17A production by CD4+ T cells was inhibited by CD4-AshR-RORγt, but not by mock-CD4-AshR-RORγt or CD4-AshR-scrambled sequence.

Conclusion

The present data in our study revealed that CD4 aptamer can serve as a delivery vehicle for shRNA that targets a specific gene in CD4+ human T cells. CD4-AshR-RORγt specifically silenced the targeted RORγt gene expression and led to a marked decrease of Th17 differentiation and IL-17 production. CD4-AshR-RORγt can be evaluated for the development of a therapeutic agent in treatment of Th17 mediated inflammatory disorders.


Disclosure:

C. Q. Chu,
None;

P. Song,
None;

Y. K. Chou,
None;

X. Zhang,
None;

R. Meza-Romero,
None;

K. Yomogida,
None;

G. Benedek,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cd4-aptamer-ror%ce%b3t-shrna-chimera-inhibits-il-17-synthesis-by-human-cd4-t-cells/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology